Urol. praxi. 2017;18(3):105-108 | DOI: 10.36290/uro.2017.024

Diagnosis and treatment of nephrotic syndrome in children

doc. MUDr. Sylva Skálová, Ph.D.1, MUDr. Jakub Zieg, Ph.D.2
Dětská klinika LF UK a FN Hradec Králové; 1
Pediatrická klinika 2. LF UK a FN Motol, Praha; 2

Nephrotic syndrome is caused by increased permeability of glomerular filtration barrier, which results in heavy proteinuria, hypoproteinemiaand edemas. The most common form in children is idiopathic nephrotic syndrome, which is further classified according to therapeutic responseto corticosteroids. Other immunosupressants (levamisol, cyclophosphamide, cyclosporin A, mycophenolate mofetil) and monoclonalantibodies (rituximab, ofatumumab) are used as steroid sparing agents in the management of complicated cases. Advances in moleculargenetics and understanding of podocyte pathophysiology changed the approach and management of hereditary nephrotic syndrome.

Keywords: nephrotic syndrome, diagnosis, management

Published: August 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Skálová S, Zieg J. Diagnosis and treatment of nephrotic syndrome in children. Urol. praxi. 2017;18(3):105-108. doi: 10.36290/uro.2017.024.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dossier C, Lapidus N, Bayer F, et al. Epidemiology of idiopathic nephrotic syndrome in children: endemic or epidemic? Pediatr Nephrol 2016, 31 (12): 2299-2308. Go to original source... Go to PubMed...
    2. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet 2003; 362: 629-639. Go to original source... Go to PubMed...
    3. Cara-Fuentes G, Clapp WL, Johnson RJ, et al. Pathogenesis of proteinuria in idiopathic minimal change disease: molecular mechanisms. Pediatr Nephrol 2016, 31(12): 2179-2289. Go to original source... Go to PubMed...
    4. Ling C, Liu X, Shen Y, et al. Urinary CD80 levels as a diagnostic biomarker of minimal change disease. Pediatr Nephrol 2015; 30(2): 309-316. Go to original source... Go to PubMed...
    5. Geier P. Nefrotický syndrom. Ped praxi 2001, 2(3): 120-123. Go to original source...
    6. Skalova S, Podhola M, Geier P, Tichy T. Renal biopsy in children with steroid-dependent nephrotic syndrome. Bratisl Lek Listy. 2009; 110(10): 647-649. Go to PubMed...
    7. Bryce A, Kerlin & Kellie Haworth, William E. Smoyer. Venous thromboembolism in pediatric nephrotic syndrome. Pediatr Nephrol 2014; 29(6): 989-997. Go to original source... Go to PubMed...
    8. Ehrich HH, Brodehl J. Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie. Eur J Pediatr 1993; 152(4): 357-361. Go to original source... Go to PubMed...
    9. Hodson EM, Knight JF, Willis NS, Craig JC. Corticosteroid therapy in nephrotic syndrome: a meta-analysis of randomised controlled trials. Arch Dis Child 2000, 83(1): 45-51. Go to original source... Go to PubMed...
    10. Latta K, von Schnakenburg C, Ehrich J. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol 2001(3); 16: 271-282. Go to original source... Go to PubMed...
    11. Larkins N, Kim S, Craig J, Hodson E. Steroid-sensitive nephrotic syndrome: an evidence-based update of immunosuppressive treatment in children. Arch Dis Child. 2016 Apr; 101(4): 404-408. Go to original source... Go to PubMed...
    12. Gipson DS, Trachtman H, Kaskel FJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults.Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int. 2011; 80(8): 868-878. Go to original source... Go to PubMed...
    13. Gellermann J, Ehrich JH, Querfeld U. Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome. Nephrol Dial Transplant. 2012; 27(5): 1970-1978 Go to original source... Go to PubMed...
    14. Basu B. Ofatamumab for rituximab-resistent nephrotic syndrome. N Engl J Med. 2014, 27; 370(13): 1268-1270. Go to original source... Go to PubMed...
    15. Kapur G, Valentini RP, Imam AA, Mattoo TK. Treatment of severe edema in children with nephrotic syndrome with diuretics alone-a prospective study. Clin J Am Soc Nephrol 2009, 4(5): 907-913. Go to original source... Go to PubMed...
    16. Trompeter RS, Lloyd BW, Hicks J, White RH, Cameron JS. Long-term outcome for children with minimal-change nephrotic syndrome. Lancet 1985; 1(8425): 368-370. Go to original source... Go to PubMed...
    17. Ishikura K, Yoshikawa N, Nakazato H, Sasaki S, Nakanishi K, Matsuyama T, et al. Morbidity in children with frequently relapsing nephrosis: 10-year follow-up of a randomized controlled trial. Pediatr Nephrol 2015; 30(3): 459-468. Go to original source... Go to PubMed...
    18. Fakhouri F, Bocquet N, Taupin P, Presne C, Gagnadoux MF, Landais P, et al. Steroid-sensitive nephrotic syndrome: from childhood to adulthood. Am J Kidney Dis 2003; 41(3): 550-557. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.